Adult-onset Still's disease secondary prevention

Jump to navigation Jump to search

Adult-onset Still's disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adult-onset Still’s Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Adult-onset Still's disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Template:Adult-onset Still's disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adult-onset Still's disease secondary prevention

CDC on Template:Adult-onset Still's disease

Template:Adult-onset Still's disease in the news

Blogs on Template:Adult-onset Still's disease

Risk calculators and risk factors for Template:Adult-onset Still's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.

Secondary Prevention

Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.[1]

References

  1. Nishina N, Kaneko Y, Kameda H, Takeuchi T (May 2015). "The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study". Mod Rheumatol. 25 (3): 401–4. doi:10.3109/14397595.2014.973659. PMID 25401229.

Template:WH Template:WS